Abstract
In the last years, results of meta-analyses and conclusive findings of systematic reviews have induced a noticeable shift of experts opinions and clinical practice from antidepressants to mood stabilizers and second generation antipsychotics as first-line treatment of borderline personality disorder (BPD). Available data on the efficacy of second generation antipsychotics in BPD are increasing and indicate a promising option in the management of this severe personality disturbance.
This review aims to report and discuss data from case reports, open label studies, and randomized controlled trials (RCTs) concerning efficacy and tolerability of second generation antipsychotics in the treatment of BPD patients. The indication of clozapine in BPD management is limited, particularly due to adverse reactions. Concerning risperidone and its metabolite paliperidone, clinical data are sparse and derive from few case reports and open investigations on small samples. Quetiapine was tested in several open label studies and showed its main clinical effect in reducing impulsivity and anger. The only RCT of ziprasidone did not find signicant differences versus placebo. At present, promising data of efficacy from RCTs are available for olanzapine and, with a lower number of trials, for aripiprazole. The majority of trials indicated that olanzapine and aripiprazole are efficacious both in treating cognitive-perceptual symptoms (a more strictly defined antipsychotic effect) and in decreasing mood instability and impulsive dyscontrol (a mood stabilizing effect).
Further investigations in large samples are needed to deal with current limitations in methods and confirm present findings and initial recommendations for clinical practice.
Keywords: Adverse effects, antipsychotics, borderline personality disorder, efficacy, meta-analysis, pharmacotherapy, randomized controlled trial, review, treatment guidelines, dyscontrolled, CLOZAPINE, RISPERIDONE, OLANZAPINE, schizoaffective disorder, ZIPRASIDONE
Current Psychopharmacology
Title: New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder
Volume: 1
Author(s): Silvio Bellino, Paola Bozzatello, Elena Brignolo and Filippo Bogetto
Affiliation:
Keywords: Adverse effects, antipsychotics, borderline personality disorder, efficacy, meta-analysis, pharmacotherapy, randomized controlled trial, review, treatment guidelines, dyscontrolled, CLOZAPINE, RISPERIDONE, OLANZAPINE, schizoaffective disorder, ZIPRASIDONE
Abstract: In the last years, results of meta-analyses and conclusive findings of systematic reviews have induced a noticeable shift of experts opinions and clinical practice from antidepressants to mood stabilizers and second generation antipsychotics as first-line treatment of borderline personality disorder (BPD). Available data on the efficacy of second generation antipsychotics in BPD are increasing and indicate a promising option in the management of this severe personality disturbance.
This review aims to report and discuss data from case reports, open label studies, and randomized controlled trials (RCTs) concerning efficacy and tolerability of second generation antipsychotics in the treatment of BPD patients. The indication of clozapine in BPD management is limited, particularly due to adverse reactions. Concerning risperidone and its metabolite paliperidone, clinical data are sparse and derive from few case reports and open investigations on small samples. Quetiapine was tested in several open label studies and showed its main clinical effect in reducing impulsivity and anger. The only RCT of ziprasidone did not find signicant differences versus placebo. At present, promising data of efficacy from RCTs are available for olanzapine and, with a lower number of trials, for aripiprazole. The majority of trials indicated that olanzapine and aripiprazole are efficacious both in treating cognitive-perceptual symptoms (a more strictly defined antipsychotic effect) and in decreasing mood instability and impulsive dyscontrol (a mood stabilizing effect).
Further investigations in large samples are needed to deal with current limitations in methods and confirm present findings and initial recommendations for clinical practice.
Export Options
About this article
Cite this article as:
Bellino Silvio, Bozzatello Paola, Brignolo Elena and Bogetto Filippo, New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder, Current Psychopharmacology 2012; 1 (1) . https://dx.doi.org/10.2174/2211556011201010086
DOI https://dx.doi.org/10.2174/2211556011201010086 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pathophysiological Role of Proteasome-Dependent Proteolytic Pathway in Endothelin-1-Related Cardiovascular Diseases
Current Vascular Pharmacology Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Status of Herbal Medicines in the Treatment of Diabetes: A Review
Current Diabetes Reviews Sedation in PACU: The Role of Benzodiazepines
Current Drug Targets "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets ABC Transporters, Bile Acids, and Inflammatory Stress in Liver Cancer
Current Pharmaceutical Biotechnology Immunotherapy for Food Allergies in Children
Current Pharmaceutical Design Cognitive Impairment in the Septic Brain
Current Neurovascular Research Analgesia and Sedation in Mechanical Ventilation in Neonatology
Current Respiratory Medicine Reviews Total Lipids and Fatty Acid Methyl Esters of Germinated Seeds of Mangrove Wild Legume
Current Nutrition & Food Science Antioxidant Activity and Chemical Components as Potential Anticancer Agents in the Olive Leaf (Olea europaea L. cv Leccino.) Decoction
Anti-Cancer Agents in Medicinal Chemistry Guanylation of Amines with Isonitriles in the Presence of Iodine
Letters in Organic Chemistry The Quality of Life of Thalassemic Patients: The Role of Endocrine Defect Compensation
Endocrine, Metabolic & Immune Disorders - Drug Targets Overlooked Issues of Snakebite Management: Time for Strategic Approach
Current Topics in Medicinal Chemistry Sepsis: The Involvement of Platelets and the Current Treatments
Current Molecular Pharmacology Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry